CGCCanopy Growth Corporation
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CGC?
Canopy Growth Corporation earns −22% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 31 points below what the capital costs: growth destroys value
- Operating margin
- −55%
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · 12 months to Q1 2027
- Share count, year on year
- +124%
Share count, year on year · shareholders own a smaller slice than a year ago
- Gross margin
- 25%
Gross margin
| Year | Operating margin |
|---|---|
| FY2021 | −227% |
| FY2022 | −214% |
| FY2023 | −789% |
| FY2024 | −77% |
| FY2025 | −44% |
| FY2026 | −57% |
Details›
- Gross margin12 months to Q1 2027
- 25%
- Operating margin12 months to Q1 2027
- −55%
- Net margin12 months to Q1 2027
- −79%
- Free cash flow margin
- −28%
- Revenue, trailing twelve months
- $294M
- Free cash flow, trailing twelve months
- −$83M
- Net income, trailing twelve months
- −$233M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −22%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #29 of 41 by RyuScore